---
title: Increase expiratory strength with SpiroGym
nct_id: NCT06942533
phase: NA
status: RECRUITING
sponsor: General University Hospital, Prague
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06942533"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06942533"
last_fetched: "2026-05-10T14:03:42.616Z"
source: "Parkinson's Pathways (curated)"
---
# Increase expiratory strength with SpiroGym

**Goal (in five words):** Increase expiratory strength with SpiroGym

**Official Title:** The Effect of Visual Feedback From the SpiroGym Mobile Application on Expiratory Muscle Strength Training Performance in Patients With Parkinson's Disease

**Trial ID:** [NCT06942533](https://clinicaltrials.gov/study/NCT06942533)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** General University Hospital, Prague
- **Target Enrollment:** 30 participants
- **Start Date:** 2025-05-01
- **Completion Date:** 2026-05-01
- **Conditions:** Parkinson Disease, Breathing Exercises, Telemedicine
- **Interventions:** EMST with SpiroGym app, EMST without SpiroGym app
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to see whether visual feedback from the SpiroGym mobile app helps people with Parkinson's get more out of expiratory muscle strength training, which aims to strengthen the muscles used for coughing and protecting the airway. Participants perform EMST, which makes you exhale against a calibrated resistance to build expiratory muscle power, and the study compares doing EMST with real-time visual cues from the app versus EMST without the app to see if feedback improves technique or performance. The trial is enrolling men and women aged 40 to 80 with Parkinson's who have been on a stable dopaminergic medication dose for at least one month, excluding those with other neurological disorders, major cognitive or psychiatric issues, prior head or neck cancer or surgery, or any acute illness during the study.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinsons disease
* Stable dopaminergic medication (stable dose for at least 1 month)

Exclusion Criteria:

* Other neurological disorders
* Significant cognitive impairment
* Major psychiatric disorder
* History of head or neck cancer or previous surgical interventions in the neck region.
* Illness during the study period
```

## Locations (2)

- General University Hospital, Prague, Czechia _(50.0880, 14.4208)_
  - Martin Srp, PhD — (CONTACT) — +420224965513 — martin.srp@vfn.cz
  - Martin Srp, PhD — (CONTACT) — 224965513 — martin.srp@vfn.cz
- Department of Neurology and Centre of Clinical Neuroscience First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia _(50.0880, 14.4208)_
  - Martin Srp, Ph.D. — (CONTACT) — +420224965513

## Central Contacts

- Martin Srp, Ph.D. — (CONTACT) — +420224965513 — martin.srp@vfn.cz

---

*Canonical: https://parkinsonspathways.com/trial/NCT06942533*  
*HTML version: https://parkinsonspathways.com/trial/NCT06942533*  
*Source data: https://clinicaltrials.gov/study/NCT06942533*